Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB

N. Matthew Ellinwood, Bethann N. Valentine, Andrew S. Hess, Jackie K. Jens, Elizabeth M. Snella, Maryam Jamil, Shannon J. Hostetter, Nicholas D. Jeffery, Jodi D. Smith, Suzanne T. Millman, Rebecca L. Parsons, Mark T. Butt, Sundeep Chandra, Martin T. Egeland, Ana B. Assis, Hemanth R. Nelvagal, Jonathan D. Cooper, Igor Nestrasil, Bryon A. Mueller, Rene LabounekAmy Paulson, Heather Prill, Xiao Ying Liu, Huiyu Zhou, Roger Lawrence, Brett E. Crawford, Anita Grover, Ganesh Cherala, Andrew C. Melton, Anu Cherukuri, Brian R. Vuillemenot, Jill C.M. Wait, Charles A. O’Neill, Jason Pinkstaff, Joseph Kovalchin, Eric Zanelli, Emma McCullagh

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Mucopolysaccharidosis type IIIB (MPS IIIB; Sanfilippo syndrome B; OMIM #252920) is a lethal, pediatric, neuropathic, autosomal recessive, and lysosomal storage disease with no approved therapy. Patients are deficient in the activity of N-acetyl-alpha-glucosaminidase (NAGLU; EC 3.2.150), necessary for normal lysosomal degradation of the glycosaminoglycan heparan sulfate (HS). Tralesinidase alfa (TA), a fusion protein comprised of recombinant human NAGLU and a modified human insulin-like growth factor 2, is in development as an enzyme replacement therapy that is administered via intracerebroventricular (ICV) infusion, thus circumventing the blood brain barrier. Previous studies have confirmed ICV infusion results in widespread distribution of TA throughout the brains of mice and nonhuman primates. We assessed the long-term tolerability, pharmacology, and clinical efficacy of TA in a canine model of MPS IIIB over a 20-month study. Long-term administration of TA was well tolerated as compared with administration of vehicle. TA was widely distributed across brain regions, which was confirmed in a follow-up 8-week pharmacokinetic/pharmacodynamic study. MPS IIIB dogs treated for up to 20 months had near-normal levels of HS and nonreducing ends of HS in cerebrospinal fluid and central nervous system (CNS) tissues. TA-treated MPS IIIB dogs performed better on cognitive tests and had improved CNS pathology and decreased cerebellar volume loss relative to vehicle-treated MPS IIIB dogs. These findings demonstrate the ability of TA to prevent or limit the biochemical, pathologic, and cognitive manifestations of canine MPS IIIB disease, thus providing support of its potential long-term tolerability and efficacy in MPS IIIB subjects.

Original languageEnglish
Pages (from-to)277-286
Number of pages10
JournalJournal of Pharmacology and Experimental Therapeutics
Volume382
Issue number3
DOIs
StatePublished - Sep 1 2022

Fingerprint

Dive into the research topics of 'Tralesinidase Alfa Enzyme Replacement Therapy Prevents Disease Manifestations in a Canine Model of Mucopolysaccharidosis Type IIIB'. Together they form a unique fingerprint.

Cite this